ES2359162T3 - Usos inmunologicos de compuestos inmunomoduladores para vacunas y terapia de enfermedades anti-infecciosas. - Google Patents

Usos inmunologicos de compuestos inmunomoduladores para vacunas y terapia de enfermedades anti-infecciosas. Download PDF

Info

Publication number
ES2359162T3
ES2359162T3 ES06824878T ES06824878T ES2359162T3 ES 2359162 T3 ES2359162 T3 ES 2359162T3 ES 06824878 T ES06824878 T ES 06824878T ES 06824878 T ES06824878 T ES 06824878T ES 2359162 T3 ES2359162 T3 ES 2359162T3
Authority
ES
Spain
Prior art keywords
vaccines
infectious disease
disease therapy
immunomodulating compounds
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES06824878T
Other languages
English (en)
Inventor
Justin B. Bertlett
George W. Muller
Peter H. Schafer
Christine Galutian
Angus G. Dalgleish
Brendan Meyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Application granted granted Critical
Publication of ES2359162T3 publication Critical patent/ES2359162T3/es
Anticipated expiration legal-status Critical
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Un compuesto, que es 4-(amino)-2-(2,6-dioxo(3-piperidil))-isoindolin-1,3-diona o 3-(4-amino-1-oxo-1,3dihidroisoindol-2-il)-piperidin-2,6-diona, para su uso para provocar una respuesta inmunitaria potenciada a partir de una vacuna en un sujeto, en el que el compuesto se formula para administrar al sujeto antes de la introducción de la vacuna en el sujeto.
ES06824878T 2005-09-01 2006-08-31 Usos inmunologicos de compuestos inmunomoduladores para vacunas y terapia de enfermedades anti-infecciosas. Active ES2359162T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71282305P 2005-09-01 2005-09-01
US712823P 2005-09-01

Publications (1)

Publication Number Publication Date
ES2359162T3 true ES2359162T3 (es) 2011-05-19

Family

ID=37806889

Family Applications (2)

Application Number Title Priority Date Filing Date
ES06824878T Active ES2359162T3 (es) 2005-09-01 2006-08-31 Usos inmunologicos de compuestos inmunomoduladores para vacunas y terapia de enfermedades anti-infecciosas.
ES11151126.7T Active ES2485316T3 (es) 2005-09-01 2006-08-31 Usos inmunológicos de compuestos inmunomoduladores para vacunas y terapia anti-enfermedades infecciosas

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES11151126.7T Active ES2485316T3 (es) 2005-09-01 2006-08-31 Usos inmunológicos de compuestos inmunomoduladores para vacunas y terapia anti-enfermedades infecciosas

Country Status (14)

Country Link
US (2) US8715677B2 (es)
EP (2) EP2301535B1 (es)
JP (2) JP2009507030A (es)
AT (1) ATE499112T1 (es)
CA (1) CA2621136C (es)
CY (1) CY1112325T1 (es)
DE (1) DE602006020300D1 (es)
DK (1) DK1928492T3 (es)
ES (2) ES2359162T3 (es)
HR (1) HRP20110348T1 (es)
PL (1) PL1928492T3 (es)
RS (1) RS51840B (es)
SI (1) SI1928492T1 (es)
WO (1) WO2007028047A2 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090068210A1 (en) * 2007-07-09 2009-03-12 Munshi Nikhil C Immunotherapy for hematological malignancies
US9200253B1 (en) * 2007-08-06 2015-12-01 Anthrogenesis Corporation Method of producing erythrocytes
ES2523925T3 (es) 2007-09-26 2014-12-02 Celgene Corporation Derivados de quinazolinona sustituidos en posición 6, 7 u 8 y composiciones que los contienen y métodos de uso de los mismos
WO2009131730A2 (en) 2008-01-31 2009-10-29 University Of Iowa Research Foundation IMMUNOGENIC COMPOSITIONS FOR ACTIVATING γδ T CELLS
US20090298882A1 (en) * 2008-05-13 2009-12-03 Muller George W Thioxoisoindoline compounds and compositions comprising and methods of using the same
EP2358697B1 (en) 2008-10-29 2015-10-21 Celgene Corporation Isoindoline compounds for use in the treatment of cancer.
US20120053159A1 (en) 2009-02-11 2012-03-01 Muller George W Isotopologues of lenalidomide
AU2010249615B2 (en) 2009-05-19 2013-07-18 Celgene Corporation Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
RU2012131164A (ru) 2009-12-22 2014-01-27 Селджин Корпорейшн (метилсульфонил)этил-бензол-изоиндолиновые производные и их терапевтическое применение
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
ES3005233T3 (en) 2010-10-01 2025-03-14 Modernatx Inc Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
CN103402980B (zh) 2011-01-10 2016-06-29 细胞基因公司 作为pde4和/或细胞因子抑制剂的苯乙基砜异吲哚啉衍生物
AU2012236655B2 (en) 2011-03-28 2016-09-22 Deuterx, Llc, 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
WO2012177678A2 (en) 2011-06-22 2012-12-27 Celgene Corporation Isotopologues of pomalidomide
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2765993B1 (en) 2011-09-14 2020-05-20 Amgen (Europe) GmbH Formulations of cyclopropanecarboxylic acid {2-[(1s)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2, 3-dihydro-1h-isoindol-4-yl}-amide
EP2763701B1 (en) 2011-10-03 2018-12-19 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
JP2015501844A (ja) 2011-12-16 2015-01-19 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 修飾ヌクレオシド、ヌクレオチドおよび核酸組成物
HUE050327T2 (hu) 2011-12-27 2020-11-30 Amgen Europe Gmbh Készítmények (+)-2-[1-(3-etoxi-4-metoxifenil)-2-metánszulfonil-etil]-4-acetilaminoizoindolin-1,3-dion tartalommal
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
WO2013151663A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of membrane proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
CA2875624A1 (en) 2012-06-06 2013-12-12 Bionor Immuno As Hiv vaccine
TWI690322B (zh) * 2012-10-02 2020-04-11 法商傳斯堅公司 含病毒的調配物及其使用
ES2921623T3 (es) 2012-11-26 2022-08-30 Modernatx Inc ARN modificado terminalmente
CA2935495C (en) 2013-01-14 2021-04-20 Deuterx, Llc 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
EP2764866A1 (en) 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Inhibitors of nedd8-activating enzyme
MX366967B (es) * 2013-03-01 2019-07-31 Astex Pharmaceuticals Inc Combinaciones de farmacos.
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
CA2907908A1 (en) 2013-04-02 2014-10-09 Celgene Corporation Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers
EP2801364A1 (en) * 2013-05-07 2014-11-12 Centre Hospitalier Universitaire Vaudois (CHUV) Salmonella strain for use in the treatment and/or prevention of cancer
EP2815749A1 (en) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
WO2015007337A1 (en) 2013-07-19 2015-01-22 Bionor Immuno As Method for the vaccination against hiv
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
WO2016005508A1 (en) 2014-07-11 2016-01-14 Bionor Immuno As Method for reducing and/or delaying pathological effects of human immunodeficiency virus i (hiv) or for reducing the risk of developing acquired immunodeficiency syndrome (aids)
US20180140694A1 (en) 2015-05-04 2018-05-24 Bionor Immuno As Dosage regimen for hiv vaccine
TWI727211B (zh) * 2018-09-27 2021-05-11 大江生醫股份有限公司 紅菽草萃取物用於提升玻尿酸合成酶之基因表現量的用途
US20230226176A1 (en) * 2020-06-26 2023-07-20 Republic Of Korea (Animal And Plant Quarantine Agency) Novel immune adjuvant and vaccine composition including the same
CN119868399B (zh) * 2025-03-21 2025-07-11 华南农业大学 杂色曲霉胞外多糖avp141-a在制备抗石斑鱼虹彩病毒的药物中的应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2444713A1 (fr) 1978-12-18 1980-07-18 Pasteur Institut Procede de production d'un adn comprenant le genome du virus de l'hepatite b et vecteur le comportant
EP0466813A4 (en) * 1989-04-05 1992-07-15 Peter Y. S Fung Active specific immunotherapy of adenocarcinomas producing immunosuppressive mucins
CA2128331A1 (en) 1992-01-21 1993-07-22 Julia L. Greenstein Methods for using histamine derivatives as immunomodulators and in immunotherapeutics
US5698579A (en) 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides
US5728385A (en) * 1993-08-12 1998-03-17 Classen Immunotherapies, Inc. Method and composition for an early vaccine to protect against both common infectious diseases and chronic immune mediated disorders or their sequelae
HU228769B1 (en) 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
US5798368A (en) 1996-08-22 1998-08-25 Celgene Corporation Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
PT2177517E (pt) 1996-07-24 2011-11-10 Celgene Corp 2-(2,6-dioxopiperidin-3-il)-ftalimida amino-substituída para redução dos níveis de tnf-alfa
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
JP4214537B2 (ja) 1996-08-12 2009-01-28 セルジーン コーポレーション 新規な免疫治療薬とこの薬物を使用してサイトカインレベルを抵減する方法
US5955476A (en) 1997-11-18 1999-09-21 Celgene Corporation Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
US5874448A (en) 1997-11-18 1999-02-23 Celgene Corporation Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels
US20010006973A1 (en) 1998-03-16 2001-07-05 Hon-Wah Man 1-oxo- and 1,3-dioxoisoindolines and method of reducing inflammatory cytokine levels
CA2361806C (en) 1999-03-18 2012-03-13 Celgene Corporation Substituted 1-oxo- and 1,3-dioxoisoindolines and their use in pharmaceutical compositions for reducing inflammatory cytokine levels
AU2593701A (en) * 1999-12-21 2001-07-03 Regents Of The University Of California, The Method for preventing an anaphylactic reaction
AUPR030800A0 (en) * 2000-09-22 2000-10-12 Pharmalink International Limited Immunomodulatory preparation
US6458810B1 (en) 2000-11-14 2002-10-01 George Muller Pharmaceutically active isoindoline derivatives
US7091353B2 (en) 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
US20030045552A1 (en) 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
US20030129161A1 (en) * 2001-09-17 2003-07-10 Hsien-Jue Chu Interleukin-12 as a veterinary vaccine adjuvant
EP1496934A4 (en) * 2002-04-19 2006-08-02 Endocyte Inc IMPROVED IMMUNOTHERAPY BY ADJUVANT
US7323479B2 (en) * 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
EP2272513A1 (en) * 2002-05-17 2011-01-12 Celgene Corporation Pharmaceutical compositions for treating cancer
AU2003282550C1 (en) * 2002-10-09 2008-09-25 Tolerx, Inc. Molecules preferentially associated with effector T cells or regulatory T cells and methods of their use
US20060240024A1 (en) * 2003-02-28 2006-10-26 The Johns Hopkins University T cell regulation
US20050048054A1 (en) * 2003-07-11 2005-03-03 Shino Hanabuchi Lymphocytes; methods
US9713375B1 (en) 2015-02-26 2017-07-25 Brett Einar Rahm Collapsible portable table

Also Published As

Publication number Publication date
US20070048327A1 (en) 2007-03-01
EP2301535B1 (en) 2014-05-28
ATE499112T1 (de) 2011-03-15
CA2621136A1 (en) 2007-03-08
JP2009507030A (ja) 2009-02-19
ES2485316T3 (es) 2014-08-13
JP5796040B2 (ja) 2015-10-21
HRP20110348T1 (hr) 2011-07-31
EP1928492A2 (en) 2008-06-11
SI1928492T1 (sl) 2011-09-30
DK1928492T3 (da) 2011-06-06
PL1928492T3 (pl) 2011-09-30
RS51840B (sr) 2012-02-29
EP2301535A1 (en) 2011-03-30
US20120190110A1 (en) 2012-07-26
CA2621136C (en) 2014-10-14
JP2013241424A (ja) 2013-12-05
CY1112325T1 (el) 2015-12-09
DE602006020300D1 (de) 2011-04-07
EP1928492B1 (en) 2011-02-23
US8715677B2 (en) 2014-05-06
WO2007028047A3 (en) 2007-06-14
WO2007028047A2 (en) 2007-03-08

Similar Documents

Publication Publication Date Title
ES2485316T3 (es) Usos inmunológicos de compuestos inmunomoduladores para vacunas y terapia anti-enfermedades infecciosas
WO2007079190A3 (en) Device and method for enhancing immune response by electrical stimulation
EP1917040A4 (en) POLYVALENT VACCINE
LTPA2011013I1 (lt) 8-[3-amino-piperidin-1-il]-ksantinai, jų gavimas ir jų panaudojimas, kaip vaistų
CY1112572T1 (el) Εμβολια γριπης που περιλαμβανουν συνδυασμους σωματιδιακων ανοσοενισχυτικων και ανοσοδιεγερτες
MA28609B1 (fr) Vaccins
DK1888107T3 (da) Hidtil ukendte vaccineformuleringer
EP1720575A4 (en) Therapeutic and diagnostic conjugates for use with multi-specific antibodies
PT1971366E (pt) Anticorpos humanos anti-il-23, composições, métodos e usos
ATE484525T1 (de) Modifizierte humane igf-1r antikörper
NO20076687L (no) Oral doseringsform
WO2010017317A3 (en) Use of mtor inhibitors to enhance t cell immune responses
EP1924282A4 (en) IMMUNIZATION OF AVIANES BY ADMINISTRATION OF NON-REPLICATED VACCINES
EP1800693A4 (en) ADJUVANT THERAPY USING ANTI-GLYPICAN-3 ANTIBODY
EP2559762A4 (en) NEW MONOCLONAL ANTIBODY AGAINST HSP90
EP2303312A4 (en) POCKEN DIA VACCINE AND ANTIGENE THEREOF TO PROMOTE IMMUNE REACTION
EP1804093A4 (en) INFRARED ABSORPTION FILTER
DK1716234T3 (da) Substitueret, ikke-kodende nukleinsyremolekyle til terapeutisk og profylaktisk immunstimulering i mennesker og højerestående dyr
DE112004000860D2 (de) Gating-Verfahren, Gating-Gerät, sowie Therapieeinrichtung
ATE520982T1 (de) Immuntest
EP1773386A4 (en) VACCINE COMPOSITIONS AND METHODS
EP1961814A4 (en) RECOMBINANT POLYVALENT VACCINE
WO2008034121A3 (en) Parasite vaccine
EP1814393A4 (en) TOLEROGENIC VACCINATE AND METHOD
EA200701166A1 (ru) Альфа-тимозиновые пептиды в качестве адъювантов противораковых вакцин